Abstract: A method for managing network service response times by a client device is provided. The client device determines whether a network service of a service provider is reachable or active and determines a service response time of the service provider. The client device communicates to the service provider a request to establish a conditional connection based on an average accept service time of a connection and a maximum service response time.

Abstract: The present invention relates to a method for preparing a multiplicity of containers of paint from a plurality of vessels separately containing an aqueous solution of a rheology modifier, an aqueous dispersion of a colorant, an aqueous dispersion of polymer particles, and an aqueous dispersion of organic polymeric microspheres. In another embodiment, the present invention relates to a method of dispensing a colorant or an opacifying agent or an inorganic extender into separate containers partially filled with a waterborne pre-paint mixture of rheology modifier, polymer particles, and organic polymeric microspheres. The process of the present invention provides a simple and cost-effective way of preparing a wide variety of a large quantity of contained and finished paints at point-of-sale.

Abstract: The present invention relates to a composition comprising an aqueous dispersion of a) polymer particles having a z-average particle size in the range of from 80 nm to 500 nm; b) polymeric crosslinked organic microspheres having a D50 particle size in the range of from 1 ?m to 30 ?m; c); a colorant and d) a zinc or zirconium compound. The composition of the present invention is useful for reducing leaching from a coating prepared from a deep base, low sheen paint formulation.

Abstract: The present invention relates to a method for preparing a multiplicity of containers of paints or pre-paints from separate vessels containing an aqueous solution of a rheology modifier, optionally an aqueous dispersion of an opacifying pigment, an aqueous dispersion of polymer particles, and an aqueous dispersion of organic polymeric microspheres. The process of the present invention provides a simple and cost-effective way of preparing a wide variety of a large quantity of contained and finished paints at point-of-sale.

Abstract: The present invention is a composition comprising a blend of a PVA based latex and an EA/MMA based polyacrylic latex. The composition of the present invention is useful in a paint formulation for providing a coating with superior scrub resistance over a formulation comprising a blend of a PVA based latex and a BA/MMA based polyacrylic latex.

Abstract: Provided are methods for preventing initiation and/or progression of gastrin-associated tumors and/or cancers in subjects. In some embodiments, the methods relate to administering compositions that gastrin immunogens to subjects. Also provided are methods for inhibiting development of gastrin-associated precancerous lesions, methods for preventing formation of fibrosis associated with a tumor and/or a cancer, uses of compositions that include a gastrin immunogen to prevent initiation and/or development of a gastrin-associated tumor or cancer and/or for preparing medicaments therefor, and compositions for use in preventing initiation and/or development of gastrin-associated tumors and/or cancers and/or precancerous lesions thereof.

Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

Abstract: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the ?7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission.

Abstract: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

Abstract: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C1-4 alkyl. The substituent at the 3-position of the 1 -azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the ?7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission.

Abstract: Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders.